Efficas: $14.5M Series B

Efficas, Inc., a biotech health, wellness and medical foods company focused on nutritional management of the immune system, has raised $14.5M in Series B funding. LSP BioVentures led the deal, and was joined by Unilever Technology Ventures and included return backers Burrill & Co., Great Spirit Ventures, JPMorgan Bay Area Equity Fund and Prolog Ventures. Seven Hills Partners served as placement agent. Since its founding in 2003 Efficas has raised approximately $23M.

Efficas’ first products include the Efficas™ Care line of medical foods that function as “leukotriene inhibitors” for the dietary management of allergic conditions such as asthma, eczema and allergies.